Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Context: Hypothalamic obesity, a treatment-resistant condition common to survivors of craniopharyngioma (CP), is strongly associated with a poor quality of life in this population. Oxytocin (OT), a hypothalamic neuropeptide, has been shown to play a role in the regulation of energy balance and to have anorexigenic effects in animal studies. Naltrexone (NAL), an opiate antagonist, has been shown to deter hedonic eating and to potentiate OT’s effects. Design: In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection. Treatment resulted in 1) reduction in body mass index (BMI) z score from 1.77 to 1.49 over 10 weeks during phase 1; 2) reduction in BMI z score from 1.49 to 0.82 over 38 weeks during phase 2; 3) reduced hyperphagia during phases 1 and 2; 4) continued hedonic high-carbohydrate food-seeking in the absence of hunger during phases 1 and 2; and 5) sustained weight reduction during decreased parental monitoring and free access to unlocked food in the home during the last 10 weeks of phase 2. Conclusion: This successful intervention of CP-related hypothalamic obesity and hyperphagia by OT alone and in combination with NAL is promising for conducting future studies of this treatment-recalcitrant form of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Social effects of oxytocin in humans: context and person matter
Bartz, J. A., Zaki, J., Bolger, N., & Ochsner, K. N. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.05.002 · Cited by 1,581 · cited 1×
“effects on obese subjects (6), and research on nonhuman primates and humans has shown an effect of OT on weight loss (7) and improved social cognition (8).”
BackgroundCassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822bead0 · Cited by 1,452
Self-citationObesity and addiction: Neurobiological overlaps
Volkow, N. D., Wang, G. ‐., Tomasi, D., & Baler, R. D. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01031.x · Cited by 800 · cited 1×
“Cravings for both food and drugs are strongly linked; both hedonic food and drug seekers share a common disruption in dopaminergic pathways (45).”
BackgroundIntranasal Oxytocin: Myths and Delusions
Leng, G., & Ludwig, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.003 · Cited by 616 · cited 1×
“shown to be significantly increased in both plasma and cerebrospinal fluid after intranasal administration in humans (29) and nonhuman primates (30), there is a question about the possibility that intranasal OTmay fail to penetrate the central nervous system (31).”
BackgroundThe effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564 · cited 1×
“In addition, opioids are known to decrease OT (16) whereas opiate antagonists,”
BackgroundStriepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., & Hurlemann, R. (2013) · Scientific Reports · doi:10.1038/srep03440 · Cited by 452 · cited 1×
“shown to be significantly increased in both plasma and cerebrospinal fluid after intranasal administration in humans (29) and nonhuman primates (30), there is a question about the possibility that intranasal OTmay fail to penetrate the central nervous system (31).”
BackgroundMechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats
Deblon, N., Veyrat-Durebex, C., Bourgoin, L., Caillon, A., Bussier, A.-L., Petrosino, S., Piscitelli, F., Legros, J.-J., Geenen, V., Foti, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025565 · Cited by 254
Oxytocin Reduces Reward-Driven Food Intake in Humans
Ott, V., Finlayson, G., Lehnert, H., Heitmann, B., Heinrichs, M., Born, J., & Hallschmid, M. (2013) · Diabetes · doi:10.2337/db13-0663 · Cited by 226
Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models
Zhang, H., Wu, C., Chen, Q., Chen, X., Xu, Z., Wu, J., & Cai, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061477 · Cited by 224
Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass
Maejima, Y., Iwasaki, Y., Yamahara, Y., Kodaira, M., Sedbazar, U., & Yada, T. (2011) · Aging · doi:10.18632/aging.100408 · Cited by 220
Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats
Morton, G. J., Thatcher, B. S., Reidelberger, R. D., Ogimoto, K., Wolden-Hanson, T., Baskin, D. G., Schwartz, M. W., & Blevins, J. E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00296.2011 · Cited by 213 · cited 1×
“(37) demonstrated that the hindbrain nucleus of the solitary tract neurons is also activated by systemic OT.”
BackgroundOxytocin reduces caloric intake in men
Lawson, E. A., Marengi, D. A., DeSanti, R. L., Holmes, T. M., Schoenfeld, D. A., & Tolley, C. J. (2015) · Obesity · doi:10.1002/oby.21069 · Cited by 208
CSF and blood oxytocin concentration changes following intranasal delivery in macaque
Dal Monte, O., Noble, P. L., Turchi, J., Cummins, A., & Averbeck, B. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103677 · Cited by 177 · cited 1×
“shown to be significantly increased in both plasma and cerebrospinal fluid after intranasal administration in humans (29) and nonhuman primates (30), there is a question about the possibility that intranasal OTmay fail to penetrate the central nervous system (31).”
BackgroundZhang, G., & Cai, D. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00196.2011 · Cited by 171 · cited 1×
“(36) found that peripheral OT activated hypothalamic OT neurons to release OT, whereas Morton et al.”
BackgroundIwasaki, Y., Maejima, Y., Suyama, S., Yoshida, M., Arai, T., Katsurada, K., Kumari, P., Nakabayashi, H., Kakei, M., & Yada, T. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00344.2014 · Cited by 148
Noble, E. E., Billington, C. J., Kotz, C. M., & Wang, C. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00118.2014 · Cited by 102 · cited 1×
“As an intervention for obesity, OT has been shown to decrease hypothalamic activity in response to highcalorie visual food cues, reduce food consumption, and increase brown adipose tissue thermogenesis and energy expenditure in lean and/or diet-induced obese rodent models (32, 39, 40).”
BackgroundSemiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity
Roth, C. L., Eslamy, H., Werny, D., Elfers, C., Shaffer, M. L., Pihoker, C., Ojemann, J., & Dobyns, W. B. (2015) · Obesity · doi:10.1002/oby.21067 · Cited by 96
Self-citationOxytocin under opioid antagonism leads to supralinear enhancement of social attention
Dal Monte, O., Piva, M., Anderson, K. M., Tringides, M., Holmes, A. J., & Chang, S. W. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702725114 · Cited by 55 · cited 1×
“conversely, have been shown to increase the release of OT (17, 18) and potentiate the effects of OT (19).”
BackgroundNeumann, I., Russell, J. A., Wolff, B., & Landgraf, R. (2008) · Neuroendocrinology · doi:10.1159/000125958 · Cited by 33
Cited by
Müller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J.-P., & Puget, S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0125-9 · Cited by 515
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71
Self-citation
Metadata
- Authors
- Hsu, E. A., Miller, J. L., Perez, F. A., & Roth, C. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-12-06
- Volume
- 103
- Issue
- 2
- Pages
- 370-375
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2772322561
- Cited by
- 86
- References
- 20
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.